Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286 million. The $5.00-per-share offer – announced at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results